hard-going emotionally because a large number of transplant recipients died. Still, ‘some of my best memories’, he recalls, ‘are of driving home at two in the morning from the ICU after a family had agreed to donate a loved one’s organs, and knowing that someone facing imminent death was being prepped for the OR’.5 A deep and abiding commitment to the eventual widespread success of organ transplantation led to Stiller's establishing the Multi-Organ Transplant Service and the Canadian Centre for Transplantation in London, over which he acted as chief from 1984 until 1996. Organ rejection was (and remains) a major challenge in the field and Stiller's key involvement as principal investigator in the early 1980s in the clinical trials and market development of the drug Cyclosporine for use as a first-line therapy for transplant rejection stands as a towering achievement in revolutionizing the success rate of organ transplants worldwide. In 1990, he published the book, Lifegifts: The Real Story of Organ Transplantation, in which he, along with his brother, the Rev’d Brian Stiller, recounts this remarkable history.6 In a similar way, Stiller's leading role amongst a team of researchers had proved in 1984 that human Type I Diabetes was an autoimmune disorder and therefore amenable to a regime of immunosuppressant or immunomodulant treatment. It was a singular breakthrough that was much-praised by the medical community, as well as by many others, including the late Professor Michael Bliss, the renowned University of Toronto medical historian and biographer of the Nobel prize-winning co-discoverer of insulin, Sir Frederick Banting.7 At the same time that Stiller was carrying out his multi-faceted hospital and laboratory work, he was helping also to enlarge steadily the capacity for advanced medical research and development in Canada. The list in this regard is long. Of especial importance is the Canadian Medical Discoveries Fund, which he founded, the largest venture capital fund in Canadian medical history, which since its inception has raised and managed over half a billion dollars in assets. In addition, Stiller's participation on medical-related boards and foundations is equally extensive. For example, he served as founder and chair of the Ontario Institute for Cancer Research, as well as the chair of Genome Canada. Along with Dr. John Evans, a former president of the University of Toronto, and Ken Knox, Stiller catalyzed the founding of the Medical and Related Science (MaRS) Discovery District in downtown Toronto, and then